Pancreatic cancer mRNA vaccine shows lasting results in an early trial

Open original

In a Phase 1 trial, personalized mRNA vaccines given after surgery triggered durable T cell responses in eight of 16 early-stage pancreatic cancer patients, with six responders alive six years later. Genentech and BioNTech have launched a Phase 2 trial while researchers study how killer and helper T cells sustain long-term immunity.

  • Personalized mRNA vaccines given after pancreatic cancer surgery produced strong T-cell responses in 8 of 16 patients, and 6 of those responders are still alive six years later.
  • Responders developed both killer and helper T cells, with helper T cells appearing key to sustaining the immune attack long-term.
  • Genentech and BioNTech have moved forward with a larger Phase 2 trial based on these early results.
  • A separate off-the-shelf KRAS-targeting vaccine triggered immune responses in about 85% of early trial participants, suggesting multiple vaccine strategies could help counter tumor evolution.

Donna Gustafson, 72, landed in Australia in February 2020 only to learn she had Stage 2 pancreatic cancer after mistaking her jaundice for jet lag. Back home in Florida she underwent surgery to remove the tumor and, just before starting standard chemotherapy, enrolled in a Phase 1 trial testing a personalized mRNA vaccine. Her tumor’s genetic material was sequenced, and researchers at Memorial Sloan Kettering teamed with Genentech and BioNTech to create nine doses meant to spur her immune system to attack any remaining cancer cells. Out of 16 patients in the trial, eight produced strong T-cell responses and six of those remain alive six years later. Two nonresponders are still alive as well. Gustafson has no sign of recurrence. The follow-up data, to be presented at the American Association for Cancer Research meeting, shows that responders not only mounted “killer” T cells but also helper T cells that seem to sustain the attack over time. Researchers caution the numbers are small and survival can vary for other reasons. But they’ve already launched a larger Phase 2 trial and are dissecting which immune signals drive success. On the side, another group is testing a off-the-shelf KRAS-targeting vaccine, which triggered immune responses in about 85% of early participants. Multiple vaccine approaches could help counter cancer’s ability to evolve around any single therapy.

Ask about this article